Pfizer sues Aurobindo and Dr Reddy’s over Ibrance (palbociclib) generics

Generics/General | Posted 27/11/2020 post-comment0

US-based pharmaceutical company, Pfizer, has filed petitions in US courts against Aurobindo Pharma and Dr Reddy’s Laboratories.

Breast cancer V15J22

Pfizer alleges that the two Indian pharmaceutical companies are separately planning to develop generic versions of its breast cancer treatment drug, Ibrance (palbociclib), before its patent expires. According to Pfizer’s 2019 annual report, Ibrance brought in almost US$5 billion revenues globally, including US$3.25 billion in the US.

The legal petitions have been filed against Aurobindo in Delaware and Dr Reddy’s in New Jersey district courts. They state that the Indian drugmakers have submitted abbreviated new drug application (ANDA) to the US Food and Drug Administration (FDA) seeking approval to engage in commercial manufacture, sale and importation of generic versions of Ibrance (in 75 mg, 100 mg, and 125 mg capsules) prior to the expiration of the 730 patent. Pfizer seeks a preliminary and permanent injunction preventing Aurobindo and Dr Reddy’s from commercial manufacture, use, sale, offer for sale, or importation of the products. In addition, the petitions seek to prevent the importation of any other drug product covered by a 730 patent into the US, prior to the expiration of that patent, including any extensions and the additional period of exclusivity.

In response, Aurobindo and Dr Reddy’s have asserted the invalidity and non-infringement of two composition related patents and a method of use patent covering palbociclib, which all expire in 2023. In addition, it has been highlighted that under Paragraph IV Patent Certifications, a company can seek FDA approval to market a generic drug before the expiration of reference drug patents.

Related articles
Inter partes review and the generic drug industry

Dr Reddy’s buys Wockhardt plant and Strides acquires 18 ANDAs

Safety of generics in US questioned

Pfizer asks US Court to reconsider generic Reglan ruling

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2020 Pro Pharma Communications International. All Rights Reserved.

Related content
Generic drug growth in Brazil and Venezuela
53 MD002445
Generics/General Posted 15/09/2023
Pharmaceutical manufacturing companies in Brazil
91 AA007225
Generics/General Posted 26/08/2022
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010